Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 30

Haemonetics Corp

HAENYSE
Trade with Public
Trade with Public
$103.96
-1.04-0.99%
가까이에: Aug 28, 5:00 PM EST
$103.80
-0.16-0.15%
시간외: Aug 28, 4:03 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Haemonetics Financials

Haemonetics (HAE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Haemonetics Q1 Adj. EPS $1.14 Beats $1.08 Estimate, Sales $339.380M Beat $327.894M Estimate

Benzinga Newsdesk

PRO
Haemonetics Widens FY2027 Sales Guidance from $1.410B-$1.427B to $1.401B-$1.441B vs $1.402B Est

Haemonetics (NYSE:HAE) widens FY2027 sales outlook from $1.410 billion-$1.427 billion to $1.401 billion-$1.441 billion vs $1.402 billion estimate.
Benzinga Newsdesk

PRO
Haemonetics Sees FY2027 Adj EPS $5.26-$5.31 vs $5.29 Est; Sees Sales $1.410B-$1.427B vs $1.394B Est

FISCAL 2027 GUIDANCEThe Company issued its fiscal 2027 GAAP total revenueand organic revenue growth guidance as follows:       Total CompanyReported Revenue4 - 7%53rd week
Benzinga Newsdesk

PRO
Haemonetics Q4 Adj. EPS $1.29 Beats $1.27 Estimate, Sales $346.351M Beat $336.862M Estimate

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.27 by 1.57 percent. This is a 4.03 percent increase over earnings of $1.24 per share from the same
Benzinga Newsdesk

These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings

Avi Kapoor

PRO
Haemonetics Sees Revenue for 2026 FY is expected to down by -3 to -1% YoY

Haemonetics (NYSE:HAE) sees Revenue for 2026 FY is expected to down by -3 to -1% YoY
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved